tradingkey.logo

Procept Biorobotics Corp

PRCT
View Detailed Chart

38.640USD

+1.140+3.04%
Close 09/11, 16:00ETQuotes delayed by 15 min
2.15BMarket Cap
LossP/E TTM

Procept Biorobotics Corp

38.640

+1.140+3.04%
Intraday
1m
30m
1h
D
W
M
D

Today

+3.04%

5 Days

+0.78%

1 Month

-0.34%

6 Months

-35.14%

Year to Date

-52.01%

1 Year

-50.53%

View Detailed Chart

TradingKey Stock Score

Currency: USD Updated2025-09-10

Key Insights

The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. The company is performing strongly in the stock market, with strong fundamentals and technicals supporting the momentum. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking
47 / 208
Overall Ranking
160 / 4730
Industry
Healthcare Equipment & Supplies

Support & Resistance

No Data

Score Analysis

Current score
Previous score

Analyst Rating

Based on 13 analysts
Buy
Current Rating
66.455
Target Price
+77.21%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks
PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 199.27% year-on-year.
Fairly Valued
The company’s latest PE is -24.17, at a medium 3-year percentile range.
Institutional Selling
The latest institutional holdings are 55.45M shares, decreasing 1.75% quarter-over-quarter.
Held by The Vanguard
Star Investor The Vanguard holds 5.24M shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.66.

News

More news coming soon, stay tuned...

Financial Indicators

EPS

No Data

Total revenue

No Data

Company

PROCEPT BioRobotics Corporation is a commercial-stage surgical robotics company. The Company is focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AQUABEAM Robotic System, an advanced, image-guided, surgical robotic system for use in minimally invasive urologic surgery with an initial focus on treating benign prostatic hyperplasia (BPH). The Company's proprietary AQUABEAM Robotic System delivers Aquablation therapy, which combines real-time, multidimensional imaging, personalized treatment planning, automated robotics and heat-free waterjet ablation for targeted and rapid removal of prostate tissue. Aquablation therapy delivers effective, safe and durable outcomes for males suffering from lower urinary tract symptoms (LUTS), due to BPH, which are independent of prostate size and shape or surgeon experience.
Ticker SymbolPRCT
CompanyProcept Biorobotics Corp
CEOMr. Larry L. Wood
Websitehttps://www.procept-biorobotics.com/
KeyAI